Related Experiment Video

Updated: Oct 25, 2025

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
12:50

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

6.7K

Anti-inflammatory effects of GLP-1 in patients with COVID-19

Saharnaz Sazgarnejad1,2,3, Niloufar Yazdanpanah1,3,4, Nima Rezaei3,4,5

  • 1School Of Medicine, Tehran University Of Medical Sciences, Tehran, Iran.

Expert Review of Anti-Infective Therapy
|August 4, 2021
PubMed
Abstract

Insights

Glucagon-like peptide 1 receptor agonist (GLP-1 RA) shows potential anti-inflammatory effects beneficial for managing COVID-19 complications. Further research into GLP-1 RA is crucial for developing new therapeutic strategies against the virus.

Area of Science:

  • Endocrinology
  • Virology
  • Immunology

Background:

  • Understanding COVID-19 pathogenesis and risk factors is crucial for effective control.
  • Inflammatory pathways play a significant role in COVID-19 pathogenesis.
  • Glucagon-like peptide 1 receptor agonist (GLP-1 RA) possesses known glucose-lowering and anti-inflammatory properties.

Purpose of the Study:

  • To evaluate the potential of GLP-1 RA as an anti-inflammatory agent in COVID-19.
  • To explore GLP-1 RA's role in mitigating COVID-19 risk factors and complications.

Main Methods:

  • Literature review of studies on GLP-1, GLP-1 RA, SARS-CoV-2, COVID-19, and inflammation.
  • PubMed database search conducted in April 2021.
  • Discussion of GLP-1 RA's effects on inflammation and COVID-19 risk factors.

Main Results:

  • GLP-1 RA exhibits anti-inflammatory effects relevant to COVID-19.
  • GLP-1 RA may help modify risk factors associated with severe COVID-19 complications.
  • The short plasma half-life of GLP-1 (2-5 minutes) due to DPP-4 degradation poses measurement challenges.

Conclusions:

  • No definitive treatment for COVID-19 currently exists.
  • Identifying promising therapeutic targets for repurposing or designing effective medications is essential.
  • GLP-1 RA represents a potential candidate for further investigation in COVID-19 treatment strategies.
Keywords:
Glucagon-like peptide 1 receptor agonistsanti-inflammatorycovid-19glp-1pro-inflammatory

More Related Videos

Inducing Acute Lung Injury in Mice by Direct Intratracheal Lipopolysaccharide Instillation11:07

Inducing Acute Lung Injury in Mice by Direct Intratracheal Lipopolysaccharide Instillation

Published on: July 6, 2019

25.7K
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

7.0K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
496
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
303
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
251
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
328
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
499
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
290